4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
B&K Corp Ltd (2396) operates in the Biotechnology industry and is headquartered in Qingdao, China with about 100 employees. Its market capitalization is roughly CNY 447 million. In the fiscal year ended 2025-12-31, 2396 reported CNY 0M in revenue and (CNY 209M) in net income.
B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 0M |
| Gross Profit | CNY 0M | CNY 0M | CNY 0M |
| Operating Income (EBIT) | (CNY 206M) | (CNY 207M) | (CNY 80M) |
| Net Income | (CNY 209M) | (CNY 212M) | (CNY 105M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | CNY 0M | CNY 0M |
| Gross Profit | CNY 0M | CNY 0M |
| Operating Income (EBIT) | (CNY 79M) | (CNY 46M) |
| Net Income | (CNY 74M) | (CNY 48M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | CNY 684M | CNY 191M | CNY 263M |
| Total Liabilities | CNY 60M | CNY 40M | CNY 395M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2396 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms